Scholars@Duke

Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.

Publication ,  Conference
Fleming, T; Borer, J; Lipicky, R; Armstrong, PW
Published in: Circulation
October 30, 2001
Published version (DOI) Link to item

Duke Scholars

Paul Wayne Armstrong
Author Paul Wayne Armstrong Medicine, Cardiology

Published In

Circulation

DOI

10.1161/hc4301.101126

EISSN

1524-4539

Publication Date

October 30, 2001

Volume

104

Issue

18

Start / End Page

E9039

Location

United States

Related Subject Headings

  • Valsartan
  • Valine
  • United States Food and Drug Administration
  • United States
  • Tetrazoles
  • Survival Rate
  • Spironolactone
  • Renal Insufficiency
  • Receptor, Angiotensin, Type 1
  • Randomized Controlled Trials as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fleming, T., Borer, J., Lipicky, R., & Armstrong, P. W. (2001). Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. In Circulation (Vol. 104, p. E9039). United States. https://doi.org/10.1161/hc4301.101126
Fleming, T., J. Borer, R. Lipicky, and P. W. Armstrong. “Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.” In Circulation, 104:E9039, 2001. https://doi.org/10.1161/hc4301.101126.
Fleming T, Borer J, Lipicky R, Armstrong PW. Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. In: Circulation. 2001. p. E9039.
Fleming, T., et al. “Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.” Circulation, vol. 104, no. 18, 2001, p. E9039. Pubmed, doi:10.1161/hc4301.101126.
Fleming T, Borer J, Lipicky R, Armstrong PW. Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. Circulation. 2001. p. E9039.

Published In

Circulation

DOI

10.1161/hc4301.101126

EISSN

1524-4539

Publication Date

October 30, 2001

Volume

104

Issue

18

Start / End Page

E9039

Location

United States

Related Subject Headings

  • Valsartan
  • Valine
  • United States Food and Drug Administration
  • United States
  • Tetrazoles
  • Survival Rate
  • Spironolactone
  • Renal Insufficiency
  • Receptor, Angiotensin, Type 1
  • Randomized Controlled Trials as Topic